Cell Therapy Technologies Market by Product (Consumables, Equipment (Single-Use Equipment, Other Equipment), Systems & Software), Process (Cell Processing), Cell Type (T-cells, Stem Cells), End User (Research Institutes) - Global Forecast to 2025
[ 173 Pages Report] The cell therapy technologies market is projected to reach USD 5.6 billion by 2025 from USD 2.8 billion in 2020, at a CAGR of 14.4% from 2020 to 2025. The emerging economies such as Australia and China are expected to provide a wide range of growth opportunities for players in the market which is driven by their large and growing populations as well as increase in the number of clinical trials and investments in the field of personalized medicine in these countries.
To know about the assumptions considered for the study, Request for Free Sample Report
COVID -19 Impact on the Cell Therapy Technologies Market
The outbreak of COVID-19 is expected to have a minimal or negligible negative impact on the cell therapy technologies market. The rise in the incidences of COVID has led to an increase in the need for an efficient drug or vaccine for COVID, which could help in reducing the severity of the cases. Cell-based research is an essential step during the manufacturing of vaccines, which can help in the growth of the market.
In the initial months of the outbreak of COVID, disruption in the supply chain had been witnessed, which has delayed the clinical trials. This can negatively impact the market to a certain extent. For instance, biopharmaceutical companies, including major players such as Pfizer and Eli Lilly, have announced clinical trial delays.
Market Dynamics
DRIVER: Rising government investments in cell-based research
The need for newer, better therapies for diseases such as cancer and CVD has resulted in an overall increase in research activity, as well as the availability of funding for cell-based research. In November 2019, the Australian government released a 10-year roadmap for stem cell research in Australia—The Stem Cell Therapies Mission. The initiative would provide USD 102 million (AU$150 million) under the Medical Research Future Fund (MRFF) to support stem cell research to deliver new therapies. Similarly, in September 2019, Innovate UK, the UK’s innovation agency, awarded a funding of USD 269,670 (GBP 267,000) to develop gel stabilization technologies, developed by Atelerix, with the first objective of extending the shelf-life of Rexgenero's cell-based therapies for storage and transport at room temperature. In the US, NIH funding for the development of cell therapies has increased significantly over the years. The favorable funding scenario is driving the demand for the equipment, media and reagents, and accessories used in cell therapy research.
RESTRAINTS: Dearth of skilled professionals
Despite technological innovation and product development over the last decade, the market has been affected by the lack of a trained workforce to operate complex instruments, such as flow cytometers and multi-mode readers. Technologically advanced and highly complex flow cytometers and spectrophotometers generate a wide array of data outputs that require expertise for interpreting and reviewing. However, there is a demand-supply gap for skilled professionals worldwide, according to the National Accrediting Agency for Clinical Laboratory Sciences (NAACLS). The UK and Europe are expected to face a serious lab skills shortage over the next decade, with medical laboratories among the worst affected. According to a research study carried out by the Gatsby Foundation, by 2030, the UK will require a further 700,000 technicians to support the economy. The shortage of skilled professionals is one of the key factors limiting the adoption and utilization of cell therapy technologies in several countries across the globe.
OPPORTUNITY: Increased focus on personalized medicine
Precision medicine is an evolving approach for disease treatment and prevention, which takes into account individual variability in genes, environments, and lifestyles. Precision medicine involves the selection of drugs wholly tailored to a patient based on disease condition and history. Although this practice is expanding into all disease areas, oncology has seen the most progress.
Precision medicine offers a new paradigm in oncology, where a patient receives personalized treatment. This approach to disease diagnosis, treatment, and prevention utilizes a universal view of patients—from their genes and their environment to their lifestyle—to make more accurate decisions.
In the field of oncology, cell-based immunotherapies, such as CAR-T therapy, are a major advancement. By eliminating, re-engineering, and reinjecting patients with their own immune cells, CAR-T cell therapy has shown remissions in cancer patients. With an increase in cancer cases, the need for personalized medicine is expected to increase in the coming years.
“Consumables is expected to hold the largest share of the cell therapy technologies market, by product in 2020”
On the basis of product, the market is segmented into consumables, equipment, and systems & software. The consumables segment accounted for the largest share of the cell therapy technologies market in 2019. Factors such as increasing investments by companies to develop advanced products as well as government initiatives for enhancing cell-based research are contributing to the growth of the cell therapy consumables market.
“T-cells is expected to hold the largest share of the cell therapy technologies market, in 2020.”
On the basis of cell type, the market is segmented into T-cells, stem cells, and other cells. In 2019, T-cells accounted for the largest share of the cell therapy technologies market. Favorable government initiatives and the increasing demand for T-cell therapies are the key factors driving the growth of this segment.
“Cell processing is expected to hold the largest share of the cell therapy technologies market in 2020”
On the basis of process, the market is segmented into cell processing; cell preservation, distribution and handling; and process monitoring and quality control. The cell processing segment dominated the market in 2019. This segment is expected to grow at the highest CAGR during the forecast period. The cell processing stage makes the highest use of cell therapy instruments and media, especially during culture media processing. This is the major factor responsible for the large share and high growth of this segment.
“Biopharmaceutical & biotechnology companies and CROs segment commanded the largest share of the cell therapy technologies market in 2020”
By end user, the cell therapy technologies market is segmented into biopharmaceutical & biotechnology companies and CROs and research institutes and cell banks. Biopharmaceutical & biotechnology companies and CROs dominate the market and are expected to grow at the highest CAGR. The large share of this regional segment can primarily be attributed to the high burden of chronic diseases and increasing R&D activities in the pharmaceutical and biotechnology industries.
To know about the assumptions considered for the study, download the pdf brochure
“North America commanded the largest share of the cell therapy technologies market in 2020.”
On the basis of region, the cell therapy technologies market is segmented into North America, Europe, Asia Pacific, and Rest of the World. In 2019, North America commanded the largest share of the cell therapy technologies market. The large share of this market segment can be attributed to the increasing incidence of CVD, increasing healthcare expenditure, growing disposable income, growing healthcare awareness, and the availability of technologically advanced devices in the region.
Key Market Players
The major players operating in this market are Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany). MaxCyte (US), Danaher Corporation (US), Becton, Dickinson and Company (US), Lonza Group (Switzerland), Sartorius AG (Germany), Terumo BCT (US), Fresenius Medical Care AG & Co. KGaA (Germany), Avantor, Inc. (US), Bio-Techne Corporation (US), Corning Incorporated (US), FUJIFILM Irvine Scientific (US), Werum IT Solutions GmbH (Germany), RoosterBio Inc. (US), SIRION Biotech GmbH (Germany), CellGenix GmbH (Germany), L7 Informatics, Inc. (US), Miltenyi Biotec GmbH (Germany), STEMCELL Technologies (Canada), Hemasoft (US), MAK-SYSTEM (US), OrganaBio, LLC (US), IxCells Biotechnology (China), and Wilson Wolf Corporation (US).
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market Size Available for Years |
2018–2025 |
|
Base Year Considered |
2019 |
|
Forecast Period |
2020–2025 |
|
Forecast Units |
Value (USD) |
|
Segments Covered |
Product, cell type, process, end-user, and region |
|
Geographies Covered |
North America (US and Canada), Europe (Germany, France, UK, Italy, Spain, and the RoE), APAC (Japan, China, Australia, and the RoAPAC), and Rest of the World. |
|
Companies Covered |
Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany). MaxCyte (US), Danaher Corporation (US), and Becton, Dickinson and Company (US), Lonza Group (Switzerland), Sartorius AG (Germany), Terumo BCT (US), Fresenius Medical Care AG & Co. KGaA (Germany), Avantor, Inc. (US), Bio-Techne Corporation (US), Corning Incorporated (US), FUJIFILM Irvine Scientific (US), MaxCyte (US), Werum IT Solutions GmbH (Germany), RoosterBio Inc. (US), SIRION Biotech GmbH (Germany), CellGenix GmbH (Germany), L7 Informatics, Inc. (US), Miltenyi Biotec GmbH (Germany), STEMCELL Technologies (Canada), Hemasoft (US), MAK-SYSTEM (US), OrganaBio, LLC (US), IxCells Biotechnology (China), and Wilson Wolf Corporation (US). |
This research report categorizes the cell therapy technologies market into the following segments and subsegments:
Cell Therapy Technologies by Product
- Consumables
- Equipment
- Cell Processing Equipment
- Single-use Equipment
- Other Equipment
- Systems & Software
Cell Therapy Technologies by Cell Type
- T-cells
- Stem Cells
- Other Cells
Cell Therapy Technologies by Process
- Cell Processing
- Cell Preservation, Distribution, and Handling
- Process Monitoring and Quality Control
Cell Therapy Technologies Market, by End User
- Biopharmaceutical & Biotechnology Companies and CROs
- Research Institutes and Cell Banks
Cell Therapy Technologies Market, by Region
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- Australia
- Rest of Asia Pacific
- Rest of the World
Key developments:
- In 2020, Lonza (Switzerland) collaborated with IsoPlexis (US) to develop the next generation of precision cell therapy manufacturing.
- In 2020, Biopharma business from General Electric Company’s Life Sciences division (US) Danaher acquired the Biopharma business from General Electric Company’s Life Sciences division. The acquisition led to a new business named Cytiva, a standalone operating company within Danaher’s Life Sciences segment.
- In 2019, Thermo Fisher Scientific invested ~USD 24 million in its Inchinnan (Scotland) site to expand its global bioproduction capabilities with additional large-volume liquid manufacturing capacity for cell culture media.
- In 2018, FUJIFILM Irvine Scientific (US) launched PRIME-XV NK Cell CDM, chemically-defined (CDM), animal component-free (ACF) medium for the ex vivo expansion of NK cells. The medium offers natural killer (NK) cell expansion while preserving NK cell potency and functionality.
- In 2017, STEMCELL Technologies signed an exclusive license with Propagenix to commercialize EpiX, an innovation empowering epithelial cell biology and cell therapy.
Frequently Asked Questions (FAQ):
What are the growth opportunities in the cell therapy technologies market across major regions in the future?
Factors such as, Emergence of iPSCs as an alternative to ESCs, increased focus on personalized medicine, and increasing public-private partnerships for the development of cell therapies are expected to offer growth opportunities in the cell therapy technologies market during the future years.
Which type of cells are expected to hold the largest share in the cell therapy technologies market?
On the basis of cell type, the market is segmented as, T-cells, stem cells and other cells. In 2019,T-cells accounted for the largest share of the cell therapy technologies market. Favorable government initiatives and the increasing demand for T-cell therapies are the key factors driving the growth of this segment.
What are the various cell therapy technologies product types and their respective market shares in the overall market?
Based on product, the market is segmented as, consumables, equipment, and systems & software. The consumables segment accounted for the largest share of the cell therapy technologies market in 2019.
Which region has a well-developed cell therapy technologies market?
The regions considered in the report are, North America, Europe, Asia Pacific, and Rest of the World. North America held the largest share owing to, the high burden of chronic diseases and increasing R&D activities in the pharmaceutical and biotechnology industries.
What is the impact of COVID-19 on cell therapy technologies market?
The market for cell therapy technologies has been minimally impacted in the initial months. However, due to the need for drugs and vaccine for the treatment of COVID-19, the market is expected to witness considerable growth during the forecast period. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 23)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.8 LIMITATIONS OF THE CURRENT EDITION
2 RESEARCH METHODOLOGY (Page No. - 27)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.1.2.1 Key data from primary sources
2.2 MARKET SIZE ESTIMATION
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 BOTTOM-UP APPROACH
FIGURE 4 CELL THERAPY TECHNOLOGIES MARKET: BOTTOM-UP APPROACH
2.2.2 GROWTH FORECAST
2.2.3 TOP-DOWN APPROACH
FIGURE 5 CELL THERAPY TECHNOLOGIES MARKET: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 DATA TRIANGULATION METHODOLOGY
2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY (Page No. - 35)
FIGURE 7 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)
FIGURE 8 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020 VS. 2025 (USD MILLION)
FIGURE 9 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020 VS. 2025 (USD MILLION)
FIGURE 10 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)
FIGURE 11 CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2020 VS. 2025 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 39)
4.1 CELL THERAPY TECHNOLOGIES: MARKET OVERVIEW
FIGURE 12 LARGE NUMBER OF ONCOLOGY-RELATED CELL THERAPY CLINICAL TRIALS TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD
4.2 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT
FIGURE 13 CONSUMABLES TO DOMINATE THE ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET IN 2019
4.3 GEOGRAPHICAL SNAPSHOT OF THE CELL THERAPY TECHNOLOGIES MARKET
FIGURE 14 CHINA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 42)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 CELL THERAPY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising government investments in cell-based research
TABLE 1 NIH FUNDING FOR CELL-BASED RESEARCH, 2016–2019 (USD MILLION)
5.2.1.2 Rising incidence of chronic and infectious diseases
FIGURE 16 GLOBAL CANCER INCIDENCE, BY REGION, 2018 VS. 2030
5.2.1.3 Large number of oncology-related cell therapy clinical trials
FIGURE 17 CANCER CELL THERAPY PIPELINE (MARCH 2019–MARCH 2020)
5.2.1.4 Increasing GMP certifications for cell therapy production facilities
TABLE 2 RISING MANUFACTURING CERTIFICATIONS AND APPROVALS FOR GMP TO BOOST THE MARKET
5.2.2 RESTRAINTS
5.2.2.1 High cost of cell-based research and low success rate
TABLE 3 COST OF CELL THERAPY EQUIPMENT
5.2.2.2 Dearth of skilled professionals
5.2.3 OPPORTUNITIES
5.2.3.1 Emergence of iPSCs as an alternative to ESCs
5.2.3.2 Increased focus on personalized medicine
5.2.3.3 Increasing public-private partnerships for the development of cell therapies
5.2.3.4 Emerging Asian markets
5.2.4 CHALLENGES
5.2.4.1 Survival of small players and new entrants
5.3 VALUE CHAIN ANALYSIS
FIGURE 18 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 19 DIRECT DISTRIBUTION—THE PREFERRED STRATEGY OF PROMINENT COMPANIES
5.5 ECOSYSTEM ANALYSIS
FIGURE 20 ECOSYSTEM ANALYSIS OF THE BIOTECHNOLOGY INDUSTRY
5.6 COVID-19 IMPACT ANALYSIS
5.7 REGULATORY LANDSCAPE
5.7.1 NORTH AMERICA
TABLE 4 NORTH AMERICA: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
5.7.2 EUROPE
TABLE 5 EUROPE: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
5.7.3 ASIA PACIFIC
TABLE 6 ASIA PACIFIC: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
5.7.4 ROW
TABLE 7 ROW: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
5.8 PRICING ANALYSIS
TABLE 8 PRICING ANALYSIS OF CELL THERAPY PROCESSING PRODUCTS (2019)
5.9 PATENT ANALYSIS
6 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT (Page No. - 59)
6.1 INTRODUCTION
TABLE 9 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
6.2 CONSUMABLES
6.2.1 HIGH REQUIREMENT OF CONSUMABLES IN PROCESSES SUPPORTS MARKET GROWTH
TABLE 10 CELL THERAPY CONSUMABLES MARKET, BY REGION, 2018–2025 (USD MILLION)
6.3 EQUIPMENT
TABLE 11 CELL THERAPY EQUIPMENT MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 12 CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2018–2025 (USD MILLION)
6.3.1 CELL PROCESSING EQUIPMENT
6.3.1.1 Cell processing equipment dominates the overall equipment market
TABLE 13 CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2018–2025 (USD MILLION)
6.3.2 SINGLE-USE EQUIPMENT
6.3.2.1 Benefits of single-use equipment have ensured end-user demand
TABLE 14 SINGLE-USE EQUIPMENT MARKET, BY REGION, 2018–2025 (USD MILLION)
6.3.3 OTHER CELL THERAPY EQUIPMENT
TABLE 15 OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION, 2018–2025 (USD MILLION)
6.4 SYSTEMS & SOFTWARE
6.4.1 SYSTEMS & SOFTWARE ARE USED TO MONITOR THE DIFFERENT STAGES OF CELL PROCESSING
TABLE 16 CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY REGION, 2018–2025 (USD MILLION)
7 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS (Page No. - 65)
7.1 INTRODUCTION
TABLE 17 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2018–2025 (USD MILLION)
7.2 CELL PROCESSING
7.2.1 CELL PROCESSING MAKES THE MOST USE OF CELL THERAPY INSTRUMENTS
TABLE 18 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2018–2025 (USD MILLION)
7.3 CELL PRESERVATION, DISTRIBUTION, AND HANDLING
7.3.1 INCREASING DEMAND FOR CELL-BASED MEDICAL PRODUCTS AND THERAPIES TO DRIVE THE GROWTH OF THE SEGMENT
TABLE 19 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY REGION, 2018–2025 (USD MILLION)
7.4 PROCESS MONITORING AND QUALITY CONTROL
7.4.1 PROCESS MONITORING IS ESSENTIAL TO ENSURE THE QUALITY AND ACCURACY OF CELL PROCESSING
TABLE 20 CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY REGION, 2018–2025 (USD MILLION)
8 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE (Page No. - 69)
8.1 INTRODUCTION
TABLE 21 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2018–2025 (USD MILLION)
8.2 T-CELLS
8.2.1 RESEARCH CONDUCTED IN THE FIELD OF CAR-T THERAPY WILL ACCELERATE THE GROWTH OF THE SEGMENT
TABLE 22 T-CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2018–2025 (USD MILLION)
8.3 STEM CELLS
8.3.1 INCREASING FUNDING IN STEM CELL RESEARCH TO DRIVE MARKET GROWTH
TABLE 23 STEM CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2018–2025 (USD MILLION)
8.4 OTHER CELLS
TABLE 24 OTHER CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2018–2025 (USD MILLION)
9 CELL THERAPY TECHNOLOGIES MARKET, BY END USER (Page No. - 73)
9.1 INTRODUCTION
TABLE 25 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
9.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS
9.2.1 RISING NUMBER OF CELL THERAPY MANUFACTURING FACILITIES TO DRIVE THE MARKET
TABLE 26 CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY REGION, 2018–2025 (USD MILLION)
9.3 RESEARCH INSTITUTES AND CELL BANKS
9.3.1 MARKET GROWTH IS SUPPORTED BY RISING RESEARCH ACTIVITY
TABLE 27 CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY REGION, 2018–2025 (USD MILLION)
10 CELL THERAPY TECHNOLOGIES MARKET, BY REGION (Page No. - 77)
10.1 INTRODUCTION
TABLE 28 CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2018–2025 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 21 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
TABLE 29 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 30 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 31 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 32 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2018–2025 (USD MILLION)
TABLE 33 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2018–2025 (USD MILLION)
TABLE 34 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
10.2.1 US
10.2.1.1 Increasing R&D activities to support market growth in the US
TABLE 35 US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 36 US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2018–2025 (USD MILLION)
TABLE 37 US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2018–2025 (USD MILLION)
TABLE 38 US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing government funding to drive the adoption of cell therapy instruments in Canada
TABLE 39 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 40 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2018–2025 (USD MILLION)
TABLE 41 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2018–2025 (USD MILLION)
TABLE 42 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
10.3 EUROPE
TABLE 43 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 44 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 45 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 46 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2018–2025 (USD MILLION)
TABLE 47 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2018–2025 (USD MILLION)
TABLE 48 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Germany holds the largest share of the European market
TABLE 49 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 50 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2018–2025 (USD MILLION)
TABLE 51 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2018–2025 (USD MILLION)
TABLE 52 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
10.3.2 UK
10.3.2.1 Favorable funding and investment scenario in the UK indicates strong growth in the coming years
TABLE 53 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 54 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2018–2025 (USD MILLION)
TABLE 55 UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2018–2025 (USD MILLION)
TABLE 56 UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Availability of government and private support is a key driver of market growth
TABLE 57 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 58 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2018–2025 (USD MILLION)
TABLE 59 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2018–2025 (USD MILLION)
TABLE 60 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Initiatives favoring cell and gene therapy development will support the market in Italy
TABLE 61 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 62 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2018–2025 (USD MILLION)
TABLE 63 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2018–2025 (USD MILLION)
TABLE 64 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Increasing funding from private and public organizations to aid market growth
TABLE 65 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 66 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2018–2025 (USD MILLION)
TABLE 67 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2018–2025 (USD MILLION)
TABLE 68 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 69 ROE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 70 ROE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2018–2025 (USD MILLION)
TABLE 71 ROE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2018–2025 (USD MILLION)
TABLE 72 ROE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 22 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
TABLE 73 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 74 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 75 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 76 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2018–2025 (USD MILLION)
TABLE 77 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2018–2025 (USD MILLION)
TABLE 78 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Increasing cell therapy-based trials to support market growth in China
TABLE 79 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 80 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2018–2025 (USD MILLION)
TABLE 81 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2018–2025 (USD MILLION)
TABLE 82 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Rising geriatric population and growing disease prevalence will drive the market in Japan
TABLE 83 JAPAN: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
TABLE 84 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 85 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2018–2025 (USD MILLION)
TABLE 86 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2018–2025 (USD MILLION)
TABLE 87 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
10.4.3 AUSTRALIA
10.4.3.1 Market in Australia to benefit from rising investments in medicine
TABLE 88 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 89 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2018–2025 (USD MILLION)
TABLE 90 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2018–2025 (USD MILLION)
TABLE 91 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 92 ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 93 ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2018–2025 (USD MILLION)
TABLE 94 ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2018–2025 (USD MILLION)
TABLE 95 ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
10.5 REST OF THE WORLD
TABLE 96 ROW: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 97 ROW: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 98 ROW: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2018–2025 (USD MILLION)
TABLE 99 ROW: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2018–2025 (USD MILLION)
TABLE 100 ROW: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
11 COMPETITIVE LANDSCAPE & COMPANY PROFILES (Page No. - 110)
11.1 COMPETITIVE LANDSCAPE
11.1.1 OVERVIEW
FIGURE 23 KEY DEVELOPMENTS IN THE CELL THERAPY TECHNOLOGIES MARKET, JANUARY 2017–SEPTEMBER 2020
FIGURE 24 MARKET EVOLUTION FRAMEWORK: JANUARY 2017 TO SEPTEMBER 2020
11.1.2 COMPETITIVE SCENARIO
11.1.2.1 Agreements, Collaborations, and Partnerships
TABLE 101 KEY AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, JANUARY 2017−SEPTEMBER 2020
11.1.2.2 Product Launches & Approvals
TABLE 102 KEY PRODUCT LAUNCHES AND APPROVALS, JANUARY 2017−SEPTEMBER 2020
11.1.2.3 Expansions
TABLE 103 KEY EXPANSIONS, JANUARY 2017−SEPTEMBER 2020
11.1.2.4 Acquisitions
TABLE 104 KEY ACQUISITIONS, JANUARY 2017−SEPTEMBER 2020
11.1.2.5 Other Developments
TABLE 105 OTHER KEY DEVELOPMENTS, JANUARY 2017−SEPTEMBER 2020
11.1.3 MARKET SHARE ANALYSIS
FIGURE 25 CELL THERAPY TECHNOLOGIES MARKET SHARE ANALYSIS, 2019
11.1.4 COMPANY EVALUATION MATRIX
FIGURE 26 CELL THERAPY TECHNOLOGIES MARKET COMPETITIVE LEADERSHIP MAPPING (2019)
11.1.5 COMPETITIVE LEADERSHIP MAPPING (START-UPS AND SMES)
FIGURE 27 CELL THERAPY TECHNOLOGIES MARKET: COMPETITIVE LEADERSHIP MAPPING (SMES AND START-UPS), 2019
11.2 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, and MnM View)*
11.2.1 THERMO FISHER SCIENTIFIC
FIGURE 28 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019)
11.2.2 MERCK KGAA
FIGURE 29 MERCK KGAA: COMPANY SNAPSHOT (2019)
11.2.3 DANAHER CORPORATION
FIGURE 30 DANAHER CORPORATION: COMPANY SNAPSHOT (2019)
11.2.4 LONZA GROUP
FIGURE 31 LONZA GROUP: COMPANY SNAPSHOT (2019)
11.2.5 SARTORIUS AG
FIGURE 32 SARTORIUS AG: COMPANY SNAPSHOT (2019)
11.2.6 TERUMO BCT, INC.
FIGURE 33 TERUMO CORPORATION: COMPANY SNAPSHOT (2019)
11.2.7 BECTON, DICKINSON AND COMPANY
FIGURE 34 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2019)
11.2.8 FRESENIUS MEDICAL CARE AG & CO. KGAA
FIGURE 35 FRESENIUS MEDICAL CARE AG & CO. KGAA: COMPANY SNAPSHOT (2019)
11.2.9 AVANTOR, INC.
FIGURE 36 AVANTOR, INC.: COMPANY SNAPSHOT (2019)
11.2.10 BIO-TECHNE CORPORATION
FIGURE 37 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2020)
11.2.11 CORNING INCORPORATED
FIGURE 38 CORNING: COMPANY SNAPSHOT (2019)
11.2.12 FUJIFILM IRVINE SCIENTIFIC
FIGURE 39 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2019)
11.2.13 MAXCYTE
FIGURE 40 MAXCYTE: COMPANY SNAPSHOT (2019)
11.2.14 WERUM IT SOLUTIONS GMBH
FIGURE 41 KÖRBER AG: COMPANY SNAPSHOT (2019)
11.2.15 ROOSTERBIO
11.2.16 SIRION BIOTECH GMBH
11.2.17 CELLGENIX GMBH
11.2.18 L7 INFORMATICS
11.2.19 MILTENYI BIOTEC GMBH
11.2.20 STEMCELL TECHNOLOGIES
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
11.2.21 HEMASOFT
11.2.22 MAK-SYSTEM
11.2.23 ORGANABIO, LLC
11.2.24 IXCELLS BIOTECHNOLOGY
11.2.25 WILSON WOLF CORPORATION
12 APPENDIX (Page No. - 166)
12.1 INDUSTRY INSIGHTS
12.2 DISCUSSION GUIDE
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 AVAILABLE CUSTOMIZATIONS
12.5 RELATED REPORTS
12.6 AUTHOR DETAILS
The study involved four major activities to estimate the current size of the cell therapy technologies market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.
Primary Research
Several stakeholders such as cell therapy technologies manufacturers, vendors, distributors, researchers, and doctors from hospitals and clinics were consulted for this report. The demand side of this market is characterized by significant use of cell therapy technologies due to rising government investments in cell-based research, increasing incidence of chronic and infectious diseases, large number of oncology-related cell therapy clinical trials, and increasing GMP certifications for cell therapy production facilities. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
BREAKDOWN OF PRIMARY PARTICIPANTS:
To know about the assumptions considered for the study, download the pdf brochure
Note 1: C-level primaries include chief executive officers (CEOs), chief operation officers (COOs), and chief financial officers (CFOs). D-level primaries include directors, managers, and heads of departments. Others include sales managers, marketing managers, and product managers.
Note 2: Company tiers are defined on the basis of their total revenues for 2019. Tier 1= < USD to and 100 EM million.< 3="< USD" Tier million, 1,000 USD million 2="USD" >
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell therapy technologies market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research
- The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the cell therapy technologies industry.
Report Objectives
- To define, describe, and forecast the cell therapy technologies market on the basis of product, cell type, process, end user, and region.
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, and opportunities, Covid-19 Impact Analysis)
- To strategically analyse micromarkets with respect to individual growth trends, prospects, and contributions to the overall cell therapy technologies market
- To analyse market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments in five geographical regions, namely, North America, Europe, the Asia Pacific, Latin America, and Rest of the World.
- To profile the key players and comprehensively analyse their product portfolios, market positions, and core competencies.
- To track and analyse competitive developments such as product launches and approvals, partnerships, expansions, and acquisitions in the cell therapy technologies market
Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographic Analysis:
- Further breakdown of the RoW, RoE, and RoAPAC segments into their respective countries for this market
Company Information:
- Detailed analysis and profiling of additional market players (up to 5)
Opportunities Assessment:
- A detailed report underlining the various growth opportunities presented in the market
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Cell Therapy Technologies Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Cell Therapy Technologies Market